Dr. Sartor on Conclusions and Future of Sipuleucel-T in Prostate Cancer

Oliver Sartor, MD
Published: Monday, Aug 28, 2017



Oliver Sartor, MD, medical oncologist at Tulane University School of Medicine, discusses conclusions drawn from an analysis of African-American patients receiving sipuleucel-T (Provenge) in metastatic castration-resistant prostate cancer (mCRPC) and the potential for combinations with this agent.

In this comparative analysis, African Americans with mCRPC receiving sipuleucel-T had a higher median overall survival when compared with Caucasian patients.

Regarding combinations with this agent, there are only hypothesized studies. There is still more to learn with sipuleucel-T, Sartor says.

   
SELECTED
LANGUAGE


Oliver Sartor, MD, medical oncologist at Tulane University School of Medicine, discusses conclusions drawn from an analysis of African-American patients receiving sipuleucel-T (Provenge) in metastatic castration-resistant prostate cancer (mCRPC) and the potential for combinations with this agent.

In this comparative analysis, African Americans with mCRPC receiving sipuleucel-T had a higher median overall survival when compared with Caucasian patients.

Regarding combinations with this agent, there are only hypothesized studies. There is still more to learn with sipuleucel-T, Sartor says.

   



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication
x